Shuttle Pharmaceuticals (US:SHPH)2026-03-31 20:05Acquisition and Business Strategy - On November 21, 2025, the company acquired substantially all assets and liabilities of Molecule.ai, a pharmaceutical software company focused on AI-driven molecular discovery and early-stage drug development[18]. - The acquisition of Molecule.ai aims to leverage AI-driven platforms for molecular discovery and early-stage drug development, improving efficiency and decision-making in drug development[102]. - The company has committed to winding down the Clinical Trials of Ropidoxuridine as part of its strategic realignment following the acquisition[102]. - The company is still evaluating the business impacts from the discontinuance of the Clinical Trials and the acquisition of Molecule.ai, which could materially affect its plans and financial position[23]. - The Molecule.ai platform includes a unified inference engine, an API-first integration layer, and a modular model framework to enhance drug discovery processes[19]. - The platform aims to integrate property prediction, biological context, multi-step reasoning, and agentic automation to accelerate early discovery while ensuring scientific reliability[21]. Financial Performance - The company reported a net loss of approximately $11.7 million and no revenues for the year ended December 31, 2025, with a working capital deficit of approximately $7.5 million[41]. - General and administrative expenses surged by 307% to $5,672,794 in 2025, primarily due to $3.5 million in investor relations advertising costs[112]. - The company reported a net loss of $11.7 million for the year ended December 31, 2025, with no revenue generated during the same period[115]. - Net loss for 2025 was $11,721,669, compared to a net loss of $9,144,797 in 2024, indicating a 28% increase in losses[169]. - The company has not generated any revenues since inception and does not expect to achieve positive cash flows from operating activities in the near future[183]. Stockholder Equity and Compliance - The company had stockholders' equity of $2,254,446 as of December 31, 2025, which was below the Nasdaq requirement of $2.5 million[34]. - Stockholders' equity reported for the fiscal quarter ended September 30, 2025, was $1,394,161, indicating non-compliance with the Stockholders' Equity Requirement[56]. - The company raised approximately $2.5 million through a private placement on November 4, 2025, which is believed to have regained compliance with the Stockholders' Equity Requirement[56]. - Following a $5.75 million equity financing in March 2025, Nasdaq acknowledged compliance with the Listing Rule 5550(b)(1)[53]. - The company faced risks of delisting from Nasdaq if it fails to meet continued listing requirements, which could adversely affect stock price and liquidity[58]. Capital Raising and Financing Activities - The company completed a public offering on March 12, 2025, raising gross proceeds of approximately $5.7 million[124]. - The company completed a private placement on June 20, 2025, raising gross proceeds of approximately $4.3 million from the sale of 21,924 shares of common stock and pre-funded warrants[125]. - The company raised $5.0 million in March 2025 and $3.9 million in June 2025 through equity offerings, contributing to its liquidity position[184]. - The company executed a 1-for-25 reverse stock split on June 16, 2025, to maintain compliance with Nasdaq's minimum bid price requirement[105]. Cash Flow and Liquidity - Cash used in operating activities for the year ended December 31, 2025, was $9.5 million, a 29% increase from $7.3 million in 2024, primarily due to a net loss of $11.7 million[130][132]. - As of December 31, 2025, cash and cash equivalents totaled $334,005, a decrease of 82.6% from $1,920,144 on December 31, 2024[193]. - The company has a working capital deficit of approximately $7.5 million as of December 31, 2025, raising concerns about its ability to continue as a going concern[115]. - The liquidity of the company's common stock may be limited, potentially affecting the ability of stockholders to sell shares and impacting stock price volatility[75]. Research and Development - Research and development expenses for Ropidoxuridine were $4,054,831 for the fiscal year ended December 31, 2025, compared to $3,618,796 for the fiscal year ended December 31, 2024[25]. - Research and development expenses increased to $4,054,831 in 2025 from $3,618,796 in 2024, a rise of 12%[169]. - Research and development expenses are charged to expense as incurred, including product development and clinical expenses, but specific figures for these expenses were not disclosed[206]. Market and Stock Performance - The stock price has been extremely volatile since trading commenced on Nasdaq, influenced by various market factors[60]. - The company does not expect to pay cash dividends in the foreseeable future, with returns dependent solely on market value increases[70]. - The company has not paid any dividends on its common stock since inception and expects to retain earnings for business development in the foreseeable future[94].